This study in Chile evaluated the impact of delayed cancer diagnoses (cervix, breast, colorectal, stomach, and prostate cancer) on cancer outcomes. The microsimulation model showed that in 2020, compared with a no-COVID-19 scenario, 6,860 (95% UI 6,045–7,768) fewer diagnoses, reflecting a 32.1% reduction. Between 2022 and 2030, this can lead to 2,073 (95% UI -86–4310) excess cancer cases. Over the same timeframe, these delays in diagnoses are expected to result in an additional 3,542 (95% UI 2,236–4,816) deaths, most of which are projected to occur before 2025. Authors suggest collaboration between multiple stakeholders to improve surge capacity over the next few years.